Sarecycline

Sarecycline
Clinical data
Trade names	Seysara
ATC code	J01AA14 (WHO) ;
Identifiers
	IUPAC name (4S,4aS,5aR,12aR)-4-(Dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;
CAS Number	1035654-66-0;
PubChem CID	71296095;
ChemSpider	28540486;
UNII	94O110CX2E;
KEGG	D10666;
ECHA InfoCard	100.241.852
Chemical and physical data
Formula	C24H29N3O8
Molar mass	487.509 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC;

Sarecycline (trade name Seysara; development code WC-3035) is a narrow-spectrum tetracycline-derived antibiotic.[1] In the United States, it was approved by the FDA in October 2018 for the treatment of moderate to severe acne vulgaris.[2]

Paratek Pharmaceuticals, Inc. licensed the US rights to sarecycline for the treatment of acne in the United States to Actavis, a subsidiary of Allergan, while retaining rights in the rest of the world.[3]

Allergan initiated a Phase 3 study in December 2014 evaluating the efficacy and safety of sarecycline tablets 1.5 mg/kg per day taken orally for 12 weeks versus placebo in the treatment of acne vulgaris.[4] Two phase 3 randomized, multi-center, double-blind, placebo-controlled studies evaluating the efficacy and safety of sarecycline in moderate to severe acne reported positive results on 27 March 2017.[5]

References

Zhanel G, Critchley I, Lin LY, Alvandi N (January 2019). "Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01297-18. PMC 6325184. PMID 30397052.
"FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.
"Paratek Pharmaceuticals Inc". Bloomberg.
Clinical trial number NCT02320149 for "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne" at ClinicalTrials.gov
"Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. 27 March 2017. Retrieved 16 May 2017.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Zhanel G, Critchley I, Lin LY, Alvandi N (January 2019). "Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris". Antimicrobial Agents and Chemotherapy. 63 (1). doi:10.1128/AAC.01297-18. PMC 6325184. PMID 30397052.

[2] "FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.

[3] "Paratek Pharmaceuticals Inc". Bloomberg.

[4] Clinical trial number NCT02320149 for "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne" at ClinicalTrials.gov

[5] "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. 27 March 2017. Retrieved 16 May 2017.